XHKG
0239
Market cap95mUSD
Oct 07, Last price
2.40HKD
1D
0.00%
1Q
3.00%
Jan 2017
-32.77%
Name
Pak Fah Yeow International Ltd
Chart & performance
P/E
8.19
P/S
3.50
EPS
0.29
Div yield, %
7.71%
Shrs. gr., 5y
—
Rev. gr., 5y
14.36%
Revenues
214m
-9.72%
Net income
91m
+16.17%
CFO
113m
+42.83%
Dividend
Sep 29, 20260.09 HKD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Pak Fah Yeow International Limited, operating with its subsidiaries, specializes in the production, promotion, and distribution of healthcare goods under the Hoe Hin brand. Its market reach spans the People's Republic of China, Hong Kong, Macau, Southeast Asia, North America, the United Kingdom, and other international territories. The company's operations are categorized into three distinct divisions: Healthcare, Property Investments, and Treasury Investments. Among its key offerings are medicated oils, such as white flower embrocation, along with various ointments and solutions for strain relief, including the floral-scented Fúzai 239 white flower embrocation. Beyond its primary healthcare focus, the firm also commits capital to diverse real estate assets, encompassing commercial, industrial, residential, and car park properties, and additionally provides advertising agency services. This enterprise, established in 1927, maintains its corporate headquarters in Wan Chai, Hong Kong.
Key people
Wee Sean Gan
Executive Chairman of the Board, Chief Executive Officer · since 2011
Chief Financial Officer · since 2009
Fock Wai Gan
Executive Director · since 2008
Cheng Hooi Gan
Business Development Manager - HHPFY, Executive Director · since 2015
Ho Kwong Tang
Head of Sales and Marketing - Hoe Hin Pak Fah Yeow Manufactory, Limited
Lai Ching Yau
Chief Operating Officer & Executive Director - Hoe Hin Pak Fah Yeow Manufactory Limited
Company Secretary · since 2009
Fook Yin Gan
Non-Executive Director · since 2015
Chi Chung Chan
Non-Executive Independent Director · since 2022
Renato Dell'orto
Non-Executive Independent Director · since 2022
Independent Non-Executive Director · since 2006
Valuation
Title HKD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||